ISSN:
1365-2036
Source:
Blackwell Publishing Journal Backfiles 1879-2005
Topics:
Medicine
Notes:
Background : Therapeutics in end-stage renal disease (ESRD) patients undergoing haemodialysis (HD) has to consider potential drug clearance during the dialysis procedure. Pegylated interferon-α (PEG-IFN-α), a middle-size protein drug active against viral hepatitis, allows convenient once-weekly dosing due to prolonged plasma half-life.Aim : To investigate the impact of permeability and dialyser pore size on PEG-IFN-α blood levels during experimental HD.Methods : Polymethylmetacrylate (PMMA) membrane 1.6 m2 dialysers with three different permeabilities/pore sizes were selected.Results : A 40 kDa PEG-IFN-α2a (PEGASYS) was not cleared (〈 5%) through low-flux/small pore size (25 Å;B3A) and high-flux/middle-large pore size (60 Å;BKP) dialysers, and was partially (≈15%) through intermediate permeability/large pore size (100 Å;BKF) dialysers. In contrast, unmodified 17 kDa IFN-α2a(Roferon-A) was removed (65%–95%) through BKP or BKF, but not B3A, PMMA dialysers. Moreover, 12 kDaPEG-IFN-α2b(PegIntron) was cleared (40%–80%) through PMMA dialysers with pore sizes ≥ 60 Å. When B3A or BKP were replaced every hour PEG-IFN-α2a plasma levels remained constant throughout three experimental-HD-sessions, but PEG-IFN-α2b was cleared partially every BKP replacement. Porosity differ among high-flux dialysers. Neither PEG-IFN-α2a nor PEG-IFN-α2b were removed after three HD sessions through (27/31/33 Å) pore size polysulphone dialysers. Although PEG-IFN-α2a was not cleared through middle pore-size (43 Å/AN69ST) polyacrylonitrile dialyser, PEG-IFN-α2b was partially removed.Conclusions : The pharmacokinetics of Peg-IFN-α may vary in a patient on dialysis.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1111/j.1365-2036.2004.02014.x
Permalink